Abstract:Understanding the mechanisms that give rise to neurodegenerative diseases, in particular Alzheimer's disease, is of fundamental importance for the development of mechanism-based therapies. Alzheimer's disease is defined by the development of extracellular deposits of beta-amyloid and intraneuronal tau inclusions. Of these, tau inclusions correlate better with the loss of cognitive function. Moreover, tau inclusions are also found in a large number of other neurodegenerative diseases, including progressive supranuclear palsy, chronic traumatic encephalopathy and Pick's disease. Of the protein assemblies characteristic of human neurodegenerative diseases, those made of tau are the most common. Tau aggregates appear to spread through the brain via interconnected nerve cells, giving rise to the concept that they do so through prion-like mechanisms. In experimental systems, such as tauopathy mouse models, the spreading of tau pathology can be recapitulated following the injection of sonicated tau seeds. However, at present it is not possible to validate the prion-like spreading hypothesis from these experiments and extrapolate to the human brain. In order to address this fundamental question, we have quantified tau amplification at the molecular level by studying the evolution of single tau aggregates in vitro over extended times and fitted this data to obtain the rate constants for fibril elongation and fragmentation . We have then developed a simple model to estimate the rate of spreading through an animal or human brain based on these rate constants. We show that the spreading efficiency of tau aggregates depends on their elongation and fragmentation rates, as well as the availability of free cytosolic tau. Importantly, our spreading model is able to recapitulate spreading times in vivo and provides, for the first time, a quantitative framework for analysing the results from animal experiments and for linking them to the development of neuropathological changes in human brain. The prion-like propagation of tau occurs by elongation and fragmentation allowing a simple model to predict the spreading rate of tau assemblies in both animal models and humans. This model shows that inhibiting the rate of tau propagation would be an effective therapeutic strategy.

Identification of protein aggregates in the aging vertebrate brain with prion-like and phase-separation properties

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Extensive accumulation of misfolded protein aggregates during natural aging and senescence

Analysis of protein levels and solubility in distinct brain regions reveals several elements of the protein homeostasis network that are impacted by aging

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases

Molecular Signatures of Neurodegenerative Diseases Identified by Proteomic and Phosphoproteomic Analyses in Aging Mouse Brain

The allure and pitfalls of the prion-like aggregation in neurodegeneration

Prion-like Mechanisms in Alzheimer's Disease.

Impaired biogenesis of basic proteins impacts multiple hallmarks of the aging brain

Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration

Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases

Correlating Protein Aggregate Structure with Cellular Function in Differentiated Muscle Cells: Discriminating Pathogenic from Non-Pathogenic Forms

Recent progress in prion and prion-like protein aggregation.

Regulated Proteolysis Induces Aberrant Phase Transition of Biomolecular Condensates into Aggregates: A Protective Role for the Chaperone Clusterin

From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins

Transcript errors generate amyloid-like proteins in huwman cells

O3‐01‐05: in vitro measurements of tau aggregate elongation and fragmentation rates allow the modelling of prion‐like spreading in humans

Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases

The Mechanism of Protein Condensation in Neurodegenerative Diseases

Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions

Distinct Region-Specific Α-Synuclein Oligomers in A53T Transgenic Mice: Implications for Neurodegeneration